Multifunctional biomolecule nanostructures for cancer therapy

Wang, Jing; Li, Yiye; Nie, Guangjun

doi:10.1038/s41578-021-00315-x

Cited by 317 publications

(204 citation statements)

References 255 publications

(320 reference statements)

Supporting

Mentioning

203

Contrasting

Unclassified

Order By: Relevance

“…There are various types of proteins that have been used in nanoparticles such as serum albumin, ferritin, lipoproteins and virus-like particles. As an effective tool in targeted drug delivery systems, studies have revealed the great potential of natural proteins in targeting specificity, pH or stimulus-induced conformational changes to achieve sustained drug effects, drug stability and synergistic effects [ 30 , 31 ]. For example, Abraxane is a well-known albumin-bound nanoparticle of paclitaxel (PTX) for clinical use to combat cancer [ 32 ].…”

Section: Design and Fabrication Of Biomimetic Nanoparticlesmentioning

confidence: 99%

Advances in Biomimetic Nanoparticles for Targeted Cancer Therapy and Diagnosis

et al. 2021

View full text Add to dashboard Cite

Biomimetic nanoparticles have recently emerged as a novel drug delivery platform to improve drug biocompatibility and specificity at the desired disease site, especially the tumour microenvironment. Conventional nanoparticles often encounter rapid clearance by the immune system and have poor drug-targeting effects. The rapid development of nanotechnology provides an opportunity to integrate different types of biomaterials onto the surface of nanoparticles, which enables them to mimic the natural biological features and functions of the cells. This mimicry strategy favours the escape of biomimetic nanoparticles from clearance by the immune system and reduces potential toxic side effects. Despite the rapid development in this field, not much has progressed to the clinical stage. Thus, there is an urgent need to develop biomimetic-based nanomedicine to produce a highly specific and effective drug delivery system, especially for malignant tumours, which can be used for clinical purposes. Here, the recent developments for various types of biomimetic nanoparticles are discussed, along with their applications for cancer imaging and treatments.

show abstract

Section: Design and Fabrication Of Biomimetic Nanoparticlesmentioning

confidence: 99%

Advances in Biomimetic Nanoparticles for Targeted Cancer Therapy and Diagnosis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In the future study, accurate and programmable nanomaterial design principles are needed to allow tissue-specific macrophages' targeting, including the capability of dealing with the dynamic phenotype changing in the complicated biological environment. The conceptualization of nanorobots, [204] some of which could be AI-mediated or intelligent drug delivery, is a potential approach to deal with the complexity. Even within the same organ, it is necessary to distinguish the subphenotypes of different macrophages, including their embryonic origin.…”

Section: Conclusion and Perspectivementioning

confidence: 99%

Use of Nanoformulation to Target Macrophages for Disease Treatment

Liu

Xie

Jiang

et al. 2021

Adv Funct Materials

View full text Add to dashboard Cite

Macrophages are abundant immune cells, which serve as a primary cell population capable of interacting with foreign substances, including engineered nanomaterials (NMs). In addition to the phagocytic activity, macrophages also play a central role in innate immunity and contribute to the initiation of adaptive immunity. Since macrophages are a natural reservoir for NMs, nanoparticles (or nano-enabled strategies) are commonly utilized to target this cell type and fine tune its polarization status in different disease scenarios. In this review, a high-level description of macrophage biology is first introduced. It is followed by the discussion on the impact of therapeutic NMs on macrophages in solid tumors and how macrophages, in turn, impact the immune system and heterogeneity in the tumor microenvironment. Another major thrust is to discuss the applications of NMs in noncancer diseases with a focus on how NMs can be used to influence macrophages in the process of tissue repair, wound healing, myocardial infarction, and certain autoimmune diseases. In addition to the design of nanocarriers to impact macrophage function, whether the same response outcome can be achieved by intrinsic NM's physicochemical properties, allowing the potential usage of the active pharmaceutical ingredient-free nanomaterials for therapeutic purposes, is also discussed.

show abstract

“…The clinical success of VYXEOS laid the foundation for more research of nanoparticle-mediated combination therapy to achieve synergistic therapeutic outcomes. In fact, the concept of co-delivery has been extended from combinations of two chemotherapeutic drugs to the co-delivery of chemotherapeutic drugs and gene therapy, immunotherapy, chemosensitizers or imaging agents for maximized therapeutic effects [46][47][48][49][50][51]. Furthermore, the ability to co-deliver therapeutic agents efficiently also proved to be effective in overcoming multidrug resistance (MDR) tumors [52,53].…”

Section: Current Trends and Potentials Of Nanomedicinesmentioning

confidence: 99%

Do Lipid-based Nanoparticles Hold Promise for Advancing the Clinical Translation of Anticancer Alkaloids?

Loh

Tan

Lee

et al. 2021

Cancers

View full text Add to dashboard Cite

Since the commercialization of morphine in 1826, numerous alkaloids have been isolated and exploited effectively for the betterment of mankind, including cancer treatment. However, the commercialization of alkaloids as anticancer agents has generally been limited by serious side effects due to their lack of specificity to cancer cells, indiscriminate tissue distribution and toxic formulation excipients. Lipid-based nanoparticles represent the most effective drug delivery system concerning clinical translation owing to their unique, appealing characteristics for drug delivery. To the extent of our knowledge, this is the first review to compile in vitro and in vivo evidence of encapsulating anticancer alkaloids in lipid-based nanoparticles. Alkaloids encapsulated in lipid-based nanoparticles have generally displayed enhanced in vitro cytotoxicity and an improved in vivo efficacy and toxicity profile than free alkaloids in various cancers. Encapsulated alkaloids also demonstrated the ability to overcome multidrug resistance in vitro and in vivo. These findings support the broad application of lipid-based nanoparticles to encapsulate anticancer alkaloids and facilitate their clinical translation. The review then discusses several limitations of the studies analyzed, particularly the discrepancies in reporting the pharmacokinetics, biodistribution and toxicity data. Finally, we conclude with examples of clinically successful encapsulated alkaloids that have received regulatory approval and are undergoing clinical evaluation.

show abstract

Multifunctional biomolecule nanostructures for cancer therapy

Cited by 317 publications

References 255 publications

Advances in Biomimetic Nanoparticles for Targeted Cancer Therapy and Diagnosis

Advances in Biomimetic Nanoparticles for Targeted Cancer Therapy and Diagnosis

Use of Nanoformulation to Target Macrophages for Disease Treatment

Do Lipid-based Nanoparticles Hold Promise for Advancing the Clinical Translation of Anticancer Alkaloids?

Contact Info

Product

Resources

About